中文
English
한국어
日本語
Español
Français
Русский
| 카탈로그 번호 | YP115036 |
|---|---|
| 설명 |
Naxitamab (YP115036) is a research-grade recombinant antibody targeting Ganglioside GD2. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| 종 반응성 | General |
| 응용 분야 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 숙주 종 | Chimeric |
| 클론성 | Monoclonal |
| 이소타입 | IgG1, kappa |
| 발현 시스템 | Mammalian cells |
| 타겟 | Ganglioside GD2 |
| 내독소 수준 | < 10 EU/mg |
| 순도 | >95% purity as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 대체 이름 | Hu3F8, Naxitamab-gqgk, CAS: 1879925-92-4 |
| 배경 | Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity. • Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer., PMID:34596246 • GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics., PMID:39921214 • Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers., PMID:38593230 • Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma., PMID:39726234 • Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma., PMID:33479234 • Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins., PMID:35008849 • RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype., PMID:32486168 • Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas., PMID:29662203 • Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma., PMID:20879881 |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |
SEC-HPLC detection for Research Grade Naxitamab.
SDS-PAGE for Research Grade Naxitamab.
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206
